Oramed Pharmaceuticals Inc. (ORMP)
| Market Cap | 85.38M |
| Revenue (ttm) | 2.00M |
| Net Income (ttm) | -28.24M |
| Shares Out | 40.85M |
| EPS (ttm) | -0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 104,189 |
| Open | 2.170 |
| Previous Close | 2.160 |
| Day's Range | 2.090 - 2.170 |
| 52-Week Range | 1.820 - 3.090 |
| Beta | 1.59 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Aug 15, 2025 |
About ORMP
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York. [Read more]
Financial Performance
Financial StatementsNews
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials a...
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, ...
Oramed Pharmaceuticals Issues Letter to Shareholders
Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials. Distribution of majority of O...
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed shareholders to receive the right to a dir...
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
NEW YORK , Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery pla...
Oramed Letter to Shareholders
Stock Repurchase Program Scilex Senior Secured Note Phase 3 Oral Insulin Trial in US JV with Chinese Partner, HTIT NEW YORK , June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (...
Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
NEW YORK , June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of...
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note with Scilex replaces Oramed's previously ...
Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally
JV will have global marketing rights to oral drug delivery technology HTIT to invest $60 million, Oramed to invest $10 million into JV HTIT to provide a supply agreement for oral insulin capsule JV to...
Oramed to Present at the 83rd American Diabetes Association Conference
NEW YORK , June 20, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it has been selected to present an oral abstract presentation at...
Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit
NEW YORK , May 18, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-per...
Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China
Oramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups NEW YORK , May 15, 2023 /PRNewswire/ -- Oramed Pharmaceu...
Oramed Pharmaceuticals Issues Shareholder Update
NEW YORK , Feb. 9, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it continues to conduct a comprehensive analysis of the data from...
Oramed's oral insulin pill fails; stock is down 72%
Shares of Oramed Pharmaceuticals Inc. ORMP, +5.78% plunged 72% in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or second...
Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes
NEW YORK , Jan. 11, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced ...
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
NEW YORK , Jan. 4, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delive...
Oramed: NASH Biotech Play With Added Bonus
Oramed achieved positive results from phase 2 study using ORMD-0801 for Type 2 Diabetes patients with NASH. Primary safety endpoint and secondary exploratory biomarker endpoints established proof of c...
Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism
NEW YORK , Nov. 29, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug deliv...
MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea
- MEDICOX secures distribution right for ORAMED's oral insulin in South Korea after phase 3 of FDA approval - Contract scale up to 18 million dollars for developmental milestone and up to 15% royalty ...
Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea
Medicox to Distribute Oramed's Oral Insulin in South Korea, if approved Oramed to Receive Up to $18 Million in Developmental Milestones Oramed to Receive up to 15% Royalties on Gross Sales Large Marke...
Oramed Reports Third Quarter 2022 Financial Results
NEW YORK , Nov. 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the de...
Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that it wi...
Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine
Primary and secondary endpoints of safety and immunogenicity met Oral vaccine elicited a potentially protective IgG response with significant seroconversion from baseline Trial shows proof of concept ...
Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Results from Oramed Pharmaceuticals's first phase 3 study ORA-D-013-1, using ORMD-0801 for the treatment of patients with Type 2 Diabetes, is expected January 2023. Results from the ongoing Cohorts A ...
Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate
Primary endpoint met: ORMD-0801 was safe and well tolerated Secondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liver fat from baseline at 12 weeks Strong evidence for treatmen...